Frank C Sciurba
Overview
Explore the profile of Frank C Sciurba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
10518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark K, Nouraie S, Lindell K, Gibson K, Sciurba F, Bon J, et al.
Ann Am Thorac Soc
. 2025 Feb;
PMID: 39946725
No abstract available.
2.
Clark K, Nouraie S, Lindell K, Gibson K, Sciurba F, Bon J, et al.
Ann Am Thorac Soc
. 2024 Nov;
PMID: 39565187
Rationale: In the United States (U.S.), ambulatory oxygen is recommended for patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) who experience symptomatic exertional hypoxemia. Ambulatory oxygen...
3.
Lovelace T, Ryu M, Jia M, Castaldi P, Sciurba F, Hersh C, et al.
EClinicalMedicine
. 2024 Sep;
75:102786.
PMID: 39263674
Background: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality. Predicting mortality risk in patients with COPD can be important for disease management strategies. Although all-cause mortality predictors...
4.
Sciurba F, Christenson S, Rheault T, Bengtsson T, Rickard K, Barjaktarevic I
Chest
. 2024 Aug;
167(2):425-435.
PMID: 39197510
Background: Exacerbations in COPD can be life-threatening and can lead to irreversible declines in lung function and quality of life. Medications that reduce exacerbation burden are an unmet need, because...
5.
Gregg R, Karoleski C, Silverman E, Sciurba F, DeMeo D, Benos P
PLoS Med
. 2024 Aug;
21(8):e1004444.
PMID: 39137208
Background: Beyond exposure to cigarette smoking and aging, the factors that influence lung function decline to incident chronic obstructive pulmonary disease (COPD) remain unclear. Advancements have been made in categorizing...
6.
Sekikawa A, Li M, Joshi N, Herbert B, Tilves C, Cui C, et al.
J Epidemiol
. 2024 Jul;
35(2):90-99.
PMID: 39034109
Background: A recent systematic review showed Japan's mortality from chronic obstructive pulmonary disease (COPD) is the lowest among 204 countries, despite notably higher smoking rates in men in Japan than...
7.
LaFon D, Helgeson E, Lindberg S, Voelker H, Bhatt S, Casaburi R, et al.
JAMA Netw Open
. 2024 May;
7(5):e247535.
PMID: 38771577
Importance: While β-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of...
8.
Kitsios G, Blacka S, Jacobs J, Mirza T, Naqvi A, Gentry H, et al.
BMJ Open
. 2024 Mar;
14(3):e077869.
PMID: 38485476
Objective: To characterise subphenotypes of self-reported symptoms and outcomes (SRSOs) in postacute sequelae of COVID-19 (PASC). Design: Prospective, observational cohort study of subjects with PASC. Setting: Academic tertiary centre from...
9.
Lovelace T, Ryu M, Jia M, Castaldi P, Sciurba F, Hersh C, et al.
medRxiv
. 2024 Feb;
PMID: 38352364
Background-research Question: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality. Predicting mortality risk in COPD patients can be important for disease management strategies. Although scores for all-cause...
10.
Connors J, Brooks M, Sciurba F, Krishnan J, Bledsoe J, Castro L, et al.
NEJM Evid
. 2024 Feb;
1(12):EVIDctcs2200149.
PMID: 38319835
Outpatient Trials in the Covid-19 Era and BeyondA group of investigators had a meeting at the National Heart, Lung, and Blood Institute in May 2020 to discuss ways to decrease...